until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.SUBJECT TO COMPLETION, DATED OCTOBER 5, 2004PROSPECTUS3,438,627 SharesCommon StockThe selling stockholders identified in this prospectus are offering for sale up to 3,438,627 shares of our Common Stock, $0.01 par value per
The shares may not be sold, nor may offers to buy be accepted prior to the time the registration statement becomes effective.The date of this prospectus is            , 2004TABLE OF CONTENTSPageProspectus Summary1Risk Factors3Forward-Looking Information17Use of Proceeds18Price Range of Common Stock18Selected Consolidated Financial Data19Management's Discussion and Analysis of Financial Condition and Results of Operations20Business33Management54Stock Performance Graph61Related Party Transactions63Principal Stockholders64Description of Capital Stock67Selling Stockholders71Plan of Distribution75Legal Matters77Experts77Where You Can Find More Information77Index to Consolidated Financial StatementsF-1The names "Acusphere," "HDDS" and "PDDS" and our logo are our trademarks.
the risk factors and consolidated financial statements and related notes included in this prospectus.Our CompanyWe are a specialty pharmaceutical company that develops new drugs and improved formulations of existing drugs using our proprietary porous microparticle
AI-700 and, subject to required regulatory approvals, we intend to manufacture AI-700 in this facility for commercial use.Private FinancingIn July 2004, we entered into definitive purchase agreements with institutional and accredited investors for a $21.5 million private placement of up
addition, commercialization of our product candidates will require us to establish sales, marketing and manufacturing capabilities, either through internal hiring or through contractual relationships
formulation development, manufacturing and clinical trials of any product candidates we develop independently or in collaboration with third parties, as well as the distribution and marketing of these
assurance that hospitals, physicians, patients or the medical community in general will accept and use any products that we may develop.If we cannot raise additional capital on acceptable terms, we may be unable to complete planned clinical trials, obtain regulatory approvals or
commercialize our product candidates.We will require substantial future capital in order to continue to conduct the research and development, clinical and regulatory activities necessary to bring our
were to be disclosed to or independently developed by a competitor, our business and financial condition could be materially adversely affected.We may become involved in lawsuits to protect or enforce our patents that would be expensive and time consuming.In order to protect or enforce our patent rights, we may initiate patent litigation against third parties in the United States or in foreign countries.
materially adversely affect our business and financial results.We have never manufactured any of our product candidates in commercial quantities, and if we fail to develop an effective manufacturing capability for
termination of our relationship with Nycomed would have a material adverse impact on our business, financial condition and results of operations.If third-party manufacturers of our products fail to devote sufficient time and resources to our concerns, or if their performance is substandard, our
withdrawal of approvals, seizures or recalls of product, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect our business.We may not be able to manufacture our products in commercial quantities, which would prevent us from marketing our products.To date our product candidates have been manufactured in small quantities for pre-clinical and clinical trials.
purchase a raw material that is in limited supply for our clinical trials, or for commercial distribution if we obtain marketing approval of a product candidate, we cannot assure you that one or more
with collaborators could delay or terminate the research and development, regulatory approval or commercialization of product candidates, or result in
product candidates will require that we provide all the funding for the cost of development and clinical trials or identify collaborators to share in the costs.In
our ultrasound contrast agent and lead product candidate, if approved for marketing and sale, will compete with nuclear stress tests, the current
in the future that could materially adversely affect our business, financial condition and results of operations.Risks Related to Our Common StockWe expect that our stock price will fluctuate significantly.We only recently completed our initial public offering.
Prohibitions on selling shares under these lock-up agreements expired on April 4, 2004.Our directors and management will exercise significant control over our company.Our directors and executive officers and their affiliates collectively control approximately 9.8% of our outstanding common stock, excluding unexercised options
The selected consolidated financial data set forth below are not necessarily indicative of our future results of operations or financial performance.Year Ended December 31,Six Months EndedJune 30,1999200020012002200320032004(in thousands, except per share data)Statement of Operations Data:Operating Expenses:Research and development expense$7,022$9,978$11,536$13,545$14,228$6,248$11,616General and administrative expense1,6222,5173,8933,9064,1731,8552,669Stock-based compensation expense5161,0762,1951,307712459Total operating expenses8,64912,51116,50519,64619,7088,81514,744Equity in loss of joint venture—(12,015)(1,965)(1,183)———Interest and other income (expense), net(492)97193(1,067)(2,215)(1,092)200Net loss(9,141)(24,429)(18,277)(21,896)(21,923)(9,907)(14,544)Accretion of dividends and offering costs on preferred stock(2,604)(4,218)(6,249)(6,666)(5,948)(3,235)—Net loss available to common stockholders$(11,745)$(28,647)$(24,526)$(28,562)$(27,871)$(13,142)$(14,544)Basic and diluted net loss per common share$(27.24)$(64.18)$(50.81)$(35.39)$(6.66)$(10.87)$(1.02)Basic and diluted weighted average common shares outstanding4324464838074,1881,20914,298As of December 31,As ofJune 30,200419992000200120022003(in thousands)Balance Sheet Data:Cash, cash equivalents and short-term investments$2,230$25,275$15,599$7,992$54,562$38,817Working capital(1,498)18,45710,7492,89950,93134,369Total assets5,10429,09224,45713,36758,92445,852Long-term debt, net of current portion4,2881,1045,2901,726205316Redeemable convertible preferred stock32,54085,00997,73991,467——Total stockholders' deficit(35,482)(64,030)(86,228)(85,348)54,37540,33819MANAGEMENT'S DISCUSSION AND ANALYSIS OFFINANCIAL CONDITION AND RESULTS OF OPERATIONSYou should read the following discussion in conjunction with our consolidated financial statements, the related notes and other financial
commercial sale of our products unless or until we or current or potential partners complete clinical trials for our products and receive marketing approval from the applicable regulatory authorities.
cash flows to be affected to any significant degree by the effect of a change in market interest rates on our investments.32BUSINESSOverviewWe are a specialty pharmaceutical company that develops new drugs and improved formulations of existing drugs using our proprietary porous microparticle
candidate is an ultrasound contrast agent in Phase III clinical development for the detection of coronary heart disease, the leading cause of death in the United States.Our